Independent and Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy Trial: Clinical Implications and Limitations
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Elevated arterial pressure is a major risk factor for progression to ESRD in diabetic nephropathy. However, the component of arterial pressure and level of BP control for optimal renal outcomes are disputed. Data from 1590 hypertensive patients with type 2 diabetes in the Irbesartan Diabetic Nephropathy Trial (IDNT), a randomized, double-blind, placebo-controlled trial performed in 209 clinics worldwide, were examined, and the effects of baseline and mean follow-up systolic BP (SBP) and diastolic BP and the interaction of assigned study medications (irbesartan, amlodipine, and placebo) on progressive renal failure and all-cause mortality were assessed. Other antihypertensive agents were added to achieve predetermined BP goals. Entry criteria included elevated baseline serum creatinine concentration up to 266 micromol/L (3.0 mg/dl) and urine protein excretion >900 mg/d. Baseline BP averaged 159/87 +/- 20/11 mmHg. Median patient follow-up was 2.6 yr. Follow-up achieved SBP most strongly predicted renal outcomes. SBP >149 mmHg was associated with a 2.2-fold increase in the risk for doubling serum creatinine or ESRD compared with SBP <134 mmHg. Progressive lowering of SBP to 120 mmHg was associated with improved renal and patient survival, an effect independent of baseline renal function. Below this threshold, all-cause mortality increased. An additional renoprotective effect of irbesartan, independent of achieved SBP, was observed down to 120 mmHg. There was no correlation between diastolic BP and renal outcomes. We recommend a SBP target between 120 and 130 mmHg, in conjunction with blockade of the renin-angiotensin system, in patients with type 2 diabetic nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Self-citationProportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management
Beckman, J. A., Creager, M. A., & Libby, P. (2002) · JAMA · doi:10.1001/jama.287.19.2570 · Cited by 2,724
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341502 · Cited by 1,766
Self-citationPeterson, J. C., Adler, S., Burkart, J. M., Greene, T., Hebert, L. A., Hunsicker, L. G., King, A. J., Klahr, S., Massry, S. G., Seifter, J. L., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-10-199511150-00003 · Cited by 1,342
Self-citationPathophysiology of Progressive Nephropathies
Remuzzi, G., & Bertani, T. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811123392007 · Cited by 1,269
Zatz, R., Dunn, B. R., Meyer, T. W., Anderson, S., Rennke, H. G., & Brenner, B. M. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112521 · Cited by 1,209
Jafar, T. H., Stark, P. C., Schmid, C. H., Landa, M., Maschio, G., de Jong, P. E., de Zeeuw, D., Shahinfar, S., Toto, R., Levey, A. S., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-4-200308190-00006 · Cited by 1,157
Glomerular hemodynamics in experimental diabetes mellitus
Hostetter, T. H., Troy, J. L., & Brenner, B. M. (1981) · Kidney International · doi:10.1038/ki.1981.33 · Cited by 790
Bakris, G. L. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.13.1555 · Cited by 469
Berl, T., Hunsicker, L. G., Lewis, J. B., Pfeffer, M. A., Porush, J. G., Rouleau, J.-L., Drury, P. L., Esmatjes, E., Hricik, D., Parikh, C. R., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-7-200304010-00010 · Cited by 402
Self-citationMogensen, C. E. (1976) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365517609055274 · Cited by 375
Atkins, R. C., Briganti, E. M., Lewis, J. B., Hunsicker, L. G., Braden, G., Champion de Crespigny, P. J., DeFerrari, G., Drury, P., Locatelli, F., Wiegmann, T. B., et al. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.10.019 · Cited by 367
Self-citationBerl, T., Hunsicker, L. G., Lewis, J. B., Pfeffer, M. A., Porush, J. G., Rouleau, J.-L., Drury, P. L., Esmatjes, E., Hricik, D., Pohl, M., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004090763 · Cited by 322
Self-citationBoutitie, F., Gueyffier, F., Pocock, S., Fagard, R., Boissel, J. P., & for the INDANA Project Steering Committee (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-6-200203190-00007 · Cited by 287
Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials
Gansevoort, R. T., Sluiter, W. J., Hemmelder, M. H., de Zeeuw, D., & de Jong, P. E. (1995) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/10.11.1963 · Cited by 259
Progression of renal insufficiency: Role of blood pressure
Brazy, P. C., Stead, W. W., & Fitzwilliam, J. F. (1989) · Kidney International · doi:10.1038/ki.1989.37 · Cited by 239
End-Stage Renal Disease Attributable to Diabetes Mellitus
Perneger, T. V., Brancati, F. L., Whelton, P. K., & Klag, M. J. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-12-199412150-00002 · Cited by 206
Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy
Lewis, J. B., Berl, T., Bain, R. P., Rohde, R. D., & Lewis, E. J. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70036-3 · Cited by 181
Self-citation“Strict” blood pressure control and progression of renal disease in hypertensive nephrosclerosis
Toto, R. D., Mitchell, H. C., Smith, R. D., Lee, H.-C., McIntire, D., & Pettinger, W. A. (1995) · Kidney International · doi:10.1038/ki.1995.361 · Cited by 164
The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics
Rodby, R. A., Rohde, R. D., Clarke, W. R., Hunsicker, L. G., Anzalone, D. A., Atkins, R. C., Ritz, E., & Lewis, E. J. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.4.487 · Cited by 131
Self-citationHayashi, K., Epstein, M., Loutzenhiser, R., & Forster, H. (1992) · Journal of the American Society of Nephrology · doi:10.1681/asn.v2111578 · Cited by 123
Hill, G. S., Heudes, D., & Bariety, J. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00831.x · Cited by 122
Angiotensin-converting enzyme inhibition in diabetic nephropathy: Ten years' experience
Parving, H., Rossing, P. R., Hommel, E. E., & Smidt, U. (1995) · American Journal of Kidney Diseases · doi:10.1016/0272-6386(95)90162-0 · Cited by 96
Sawicki, P. T., M??hlhauser, I., Didjurgeit, U., Baumgartner, A., Bender, R., & Berger, M. (1995) · Journal of Hypertension · doi:10.1097/00004872-199508000-00015 · Cited by 57
Hasebe, N., Shinsuke, K. I. D. O., Ido, A., & Kikuchi, K. (2002) · Hypertension Research · doi:10.1291/hypres.25.381 · Cited by 20
Cited by
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,824
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
“140mmHg in patients with DM2 has been associated with higher risk of ESRD and death (23,24).”
Metadata
- Authors
- Pohl, M. A., Blumenthal, S., Cordonnier, D. J., De Alvaro, F., DeFerrari, G., Eisner, G., Esmatjes, E., Gilbert, R. E., Hunsicker, L. G., de Faria, J. B. L., Mangili, R., Moore, J., Reisin, E., Ritz, E., Schernthaner, G., Spitalewitz, S., Tindall, H., Rodby, R. A., & Lewis, E. J.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2005-10
- Volume
- 16
- Issue
- 10
- Pages
- 3027-3037
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2140926653
- Cited by
- 375
- References
- 30
- FWCI
- 16.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.